Investigational drug · Phase 2
CIT-013
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hidradenitis Suppurativa (HS), Rheumatoid Arthritis.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
4
Any phase or sponsor naming "CIT-013"
First trial start
2025
Jul 29, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CIT-013", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hidradenitis Suppurativa (HS)
- Rheumatoid Arthritis
Approved drugs for the same conditions: Rheumatoid arthritis · Hidradenitis suppurativa · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "CIT-013" as an intervention, largest first.
- A Study With CIT-013 in HS PatientsPivotal-lookingActive, not recruiting
Citryll BVIndustry
NCT06993233 · 108 participants · Start Oct 31, 2025 · Primary completion Apr 2027
Drug: CIT-013 high dose; CIT-013 medium dose and 1 more · For: Hidradenitis Suppurativa (HS)
Sites: Barrie, Canada; Calgary, Canada; London, Canada · 28 sites in all
- A Study With CIT-013 in RA PatientsCompleted
Citryll BVIndustry
NCT06567470 · 96 participants · Start Jul 29, 2025 · Primary completion Jul 2, 2026
Drug: CIT-013 low dose; CIT-013 high dose and 2 more · For: Rheumatoid Arthritis
Sites: Leuven, Belgium; Bamberg, Germany; Berlin, Germany · 20 sites in all
Citryll BVIndustry
NCT07499908 · 10 participants · Start Jun 23, 2026 · Primary completion Aug 10, 2026
Drug: CIT-013 high dose; Placebo · For: Healthy Adult
Sites: Groningen, Netherlands
Citryll BVIndustry
NCT07147959 · 7 participants · Start Jan 15, 2026 · Primary completion Jul 15, 2026
Drug: [89Zr]Zr-CIT · For: RA
Sites: Nijmegen, Netherlands
Newest research
PubMed records naming it or its code names, newest first.
- Immunothrombosis promotes the interaction between neutrophils and synovial fibroblasts in rheumatoid arthritis.
Papadimitriou E, Natsi AM, Tsironidou V, et al. · Transl Res 2026
- Phase I trial in participants with rheumatoid arthritis and healthy volunteers with CIT-013, a first-in-class extracellular traps targeted therapy.
Ronner MN, Klarenbeek NB, Hadi S, et al. · EULAR Rheumatol Open 2026
- Targeting Neutrophil Function as Therapy for Hidradenitis Suppurativa.
Meldrum E, Ingram JR · Int J Mol Sci 2026
- A Web of Challenges: The Therapeutic Struggle to Target NETs in Disease.
Espiritu A, O'Sullivan KM · Int J Mol Sci 2025
- Inhibition of EETosis with an anti-citrullinated histone antibody: a novel therapeutic approach for eosinophilic inflammatory disorders.
Zwiers E, Montizaan D, Kip A, et al. · Front Immunol 2025
- Real-Time, High-Throughput Microscopic Quantification of Human Neutrophil Extracellular Trap Release and Assessing the Pharmacology of Antagonists.
van der Linden M, Kumari S, van Dalen S, et al. · J Vis Exp 2024
Also in development for Hidradenitis Suppurativa (HS)
- PovorcitinibINCB054707, INCB54707Phase 312 trials
Incyte · Hidradenitis Suppurativa (HS), NonSegmental Vitiligo, Prurigo Nodularis
- BFB759Phase 32 trials
Bluefin Biomedicine, Inc. · Atopic Dermatitis (AD), Hidradenitis Suppurativa (HS)
- LT-002-158Phase 23 trials
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. · Atopic Dermatitis (AD), Hidradenitis Suppurativa (HS)
- ORKA-002Phase 23 trials
Oruka Therapeutics, Inc. · Plaque Psoriasis, Hidradenitis Suppurativa (HS)
- CIT-013 dosePhase 22 trials
Citryll BV · Hidradenitis Suppurativa (HS), Rheumatoid Arthritis
- SL-325Phase 22 trials
Shattuck Labs, Inc. · Crohn's Disease, Hidradenitis Suppurativa (HS)
- SPY002-072SPY072Phase 22 trials
Spyre Therapeutics, Inc. · Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis
- TibulizumabZB-106Phase 22 trials
Zura Bio Inc · Hidradenitis Suppurativa (HS), Systemic Sclerosis (SSc), Scleroderma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.